Samaan MA, Cunningham G, Lim SH, Dawson P, et al. Fecal loss of vedolizumab is associated with ulcerative colitis severity, lower serum vedolizumab levels, and rates of clinical response: results from the FAVOUR study. J Crohns Colitis 2025;19:jjaf159.
PMID: 40891876